trending Market Intelligence /marketintelligence/en/news-insights/trending/grt64r4tytFRin8mfW0eSQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Lilly's Emgality wins US FDA nod as 1st therapy for episodic cluster headaches

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Lilly's Emgality wins US FDA nod as 1st therapy for episodic cluster headaches

The U.S. Food and Drug Administration approved Eli Lilly and Co.'s Emgality as the first drug for treating episodic cluster headaches in adults.

Cluster headaches are recurrent attacks of severe headaches on one side of the head, frequently associated with pain behind or around one eye, restlessness and agitation. The attacks typically last 15 to 180 minutes and can occur many times a day during a cluster period.

Emgality, or galcanezumab, is an under-the-skin injection that can be self-administered once a month.

The FDA's approval for Emgality is based on a phase 3 study, which showed that the drug helped reduce weekly episodes of cluster headaches.

Emgality is already approved for preventing migraine in adults. The U.S. FDA granted a breakthrough-therapy designation to Emgality in September 2018 and a priority review status in March 2019.